Core Viewpoint - The company, Berry Genomics, has signed a maximum guarantee contract with Hangzhou United Bank for a credit facility of 40 million yuan for its wholly-owned subsidiary, Hangzhou Berry [1] Group 1 - The total amount of external guarantees provided by the company and its subsidiaries is 307 million yuan, which includes the recent guarantee [1] - This total guarantee amount represents 18.28% of the company's most recent audited net assets [1]

成都市贝瑞和康基因技术股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人： 高扬 主管会计工作的负责人： 王冬 会计机构负责人： 高莉 | 非经营性资金占用 | 资金占用方 名称 | 占用方与上 市公司的关 联关系 | 上市公司核算的会计科目 | 2025 年期 初往来资 金余额 | 2025 年 1-6 月 往来累 计发生 金额 （不含 利息） | 2025 年 1-6 月 往来资 金的利 息(如 有) | 2025 年 1-6 月偿还累计 发生金额 | 2025 年 6 月 30 日 往来资金余额 | 占用形成 原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 控股股东、实际控 | | | | | | | | | | | | 制人 及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 前控股股东、实际 | | | | | | | | | | | | 控制人 | | | | | ...

成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告全文 成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 成都市贝瑞和康基因技术股份有限公司 2025 年半年度财务报告全文 财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：成都市贝瑞和康基因技术股份有限公司 2025 年 06 月 30 日 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 359,908,471.56 | 383,071,864.35 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 10,479,041.92 | 17,032,640.72 | | 衍生金融资产 | | | | 应收票据 | 6,414,646.08 | 2,587,200.00 | | 应收账款 | 659,878,630.79 | 692,131,312.99 | | 应收款项融资 | | ...

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-046 成都市贝瑞和康基因技术股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保审批情况概述 成都市贝瑞和康基因技术股份有限公司（以下简称"贝瑞基因""公司"） 于 2025 年 8 月 20 日召开第十届董事会第十六次会议审议通过了《关于为全资 子公司提供担保的议案》。公司之全资子公司杭州贝瑞和康基因诊断技术有限 公司（以下简称"杭州贝瑞"）向杭州联合农村商业银行股份有限公司高沙支 行（以下简称"杭州联合银行高沙支行"）申请综合授信 4,000 万元，授信期 限 1 年。公司同意为杭州贝瑞使用上述授信所形成的债务提供连带责任保证担 保。具体内容详见公司于 2025 年 8 月 21 日在巨潮资讯网上披露的《关于为全 资子公司提供担保的公告》（公告编号：2025-042）。 5、法定代表人：高扬 6、注册资本：11,500 万元人民币 7、注册地点：浙江省杭州经济技术开发区白杨街道 6 号大街 260 号 9 幢,16 幢一层、二层 8、经营 ...

Financial Performance - The company's operating revenue for the first half of 2025 was ¥447,434,341.07, representing a decrease of 18.91% compared to ¥551,776,302.07 in the same period last year[18]. - The net loss attributable to shareholders for the first half of 2025 was ¥27,242,543.15, a decline of 394.11% from a profit of ¥9,262,843.84 in the previous year[18]. - The net cash flow from operating activities was negative at ¥31,902,432.23, a decrease of 341.76% compared to a positive cash flow of ¥13,195,640.30 in the same period last year[18]. - Basic and diluted earnings per share for the first half of 2025 were both -¥0.0771, down 394.27% from ¥0.0262 in the previous year[18]. - The company achieved revenue of ¥447,434,341.07 in the first half of 2025, with a net profit attributable to shareholders of -¥27,242,543.15[47]. - The company's revenue for the reporting period was ¥447,434,341.07, a decrease of 18.91% compared to ¥551,776,302.07 in the same period last year[60]. - The company reported a significant increase in credit impairment losses by 80.08% to -¥15,756,033.26, attributed to lower collection rates from major clients[66]. - The total comprehensive income decreased from ¥12,977,621.95 to a loss of ¥29,360,673.05, indicating a significant downturn[152]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,422,090,357.68, an increase of 1.57% from ¥2,384,723,994.06 at the end of the previous year[18]. - The net assets attributable to shareholders decreased by 2.11% to ¥1,643,967,241.41 from ¥1,679,476,362.94 at the end of the previous year[18]. - Total liabilities rose to ¥741,261,590.68, up from ¥669,562,176.39, marking an increase of around 10.70%[144]. - Owner's equity totaled ¥1,680,828,767.00, down from ¥1,715,161,817.67, showing a decrease of about 2.00%[144]. - The company reported a total current assets balance of ¥1,383,056,439.13 as of June 30, 2025, down from ¥1,439,086,278.92 at the beginning of the period, representing a decrease of approximately 3.9%[142]. Cash Flow - Operating cash flow for the first half of 2025 was negative at -¥31,902,432.23, compared to a positive 13,195,640.30 in the same period of 2024, indicating a decline in operational efficiency[157]. - Cash inflow from financing activities increased to 149,260,233.43 CNY in 2025 from 99,996,255.68 CNY in 2024, showing a growth of approximately 49%[158]. - The company reported a total cash outflow of -¥19,284,848.07 for the first half of 2025, an improvement compared to -¥49,888,963.87 in the same period of 2024[158]. Research and Development - The company is actively involved in research and development of new products and technologies to enhance its genetic testing capabilities[25]. - Research and development expenses increased from ¥39,768,904.04 to ¥52,519,317.48, an increase of approximately 32%[151]. - The company aims to increase its R&D expenditure by 17.51% in the upcoming fiscal year to drive innovation[172]. Market Strategy and Expansion - The company plans to expand its market presence by leveraging its proprietary sequencing platforms and comprehensive service offerings[25]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[165]. - The company plans to expand its market presence by entering two new regions in the next quarter[165]. Product Offerings - The company focuses on high-throughput sequencing technology and third-generation HiFi sequencing technology for genetic testing services and related equipment, reagents, and software sales[25]. - The company offers a comprehensive range of genetic testing services, including over 1,700 single-gene hereditary diseases and various prenatal and newborn screening tests[26]. - The company has established a comprehensive range of sequencing analysis services, utilizing leading gene sequencing platforms such as Illumina NovaSeq X Plus and PacBio Revio[30]. Risks and Challenges - The company highlighted risks and challenges in its future operations, which are detailed in the management discussion section[4]. - The company faces risks from intensified market competition and declining service prices, which could impact future performance[83]. - The company is at risk of technological and product innovation lag, which may affect market share and profitability[84]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[92]. - The total number of ordinary shareholders at the end of the reporting period was 68,183[131]. - The largest shareholder, Chengdu Tianxing Instrument (Group) Co., Ltd., held a 12.45% stake, amounting to 44,002,000 shares, which were pledged[131].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][4]. Core Insights - The company focuses on reproductive health and genetic disease testing, providing a comprehensive solution of "products + services" and is a leading player in the domestic genetic testing field [1][15]. - The market for life science sequencing solutions in China is expected to grow at a compound annual growth rate (CAGR) of 14.9% from 2018 to 2023, reaching 138.8 billion yuan by 2033, indicating potential for the company's continued market penetration [1]. - The company is leveraging its data and technology to build competitive barriers in the AI healthcare industry, with the AI medical market projected to reach 11.43 billion yuan by 2025 and 28.61 billion yuan by 2027 [2]. Summary by Sections Company Overview and Business Layout - The company, established in 2010 and listed in 2017, began with non-invasive prenatal testing (NIPT) and has expanded into genetic disease testing and research services [15]. - It utilizes high-throughput sequencing and third-generation HiFi sequencing technologies to provide genetic testing services and related equipment, reagents, and software [15]. Industry Development and Core Business - The company’s core business includes high-throughput sequencing technology and third-generation sequencing services, focusing on reproductive health and genetic disease testing [40]. - The company has established a comprehensive service model for hospitals and third-party laboratories, integrating advanced sequencing technology with AI applications [40]. Financial Performance and Forecast - The company’s revenue is projected to be 1.05 billion yuan in 2025, with a gradual increase to 1.42 billion yuan by 2027, while net profit is expected to improve from a loss of 140 million yuan in 2025 to a profit of 400 million yuan in 2027 [3][4]. - The company’s gross margin has shown an upward trend, increasing from 42.72% in 2022 to 46.86% in 2024, driven by a higher proportion of reagent sales [29]. AI Medical Sector - The company is positioned to capitalize on the AI medical sector, with its GENOisi™ intelligent model facilitating a smart data management and clinical decision-making process [2][20]. - The AI medical market is rapidly expanding, supported by favorable domestic policies, and the company aims to leverage its extensive clinical data and self-developed algorithms for commercial applications [2].

Group 1 - The stock price of Berry Genomics closed at 15.94 yuan on August 26, 2025, down 4.03% from the previous trading day, with a trading volume of 977 million yuan [1] - Berry Genomics operates in the medical device, AI pharmaceutical, and assisted reproduction sectors, focusing on the research and application of gene sequencing technology [2] - The company's subsidiary, Hangzhou Berry Health and Technology Co., Ltd., recently received a medical device registration certificate from the National Medical Products Administration for its NovaSeq6000Dx-CN-BG gene sequencer, which meets various gene testing needs for the prevention of birth defects [2] Group 2 - On August 26, 2025, the main capital outflow for Berry Genomics was 193 million yuan, accounting for 3.71% of its circulating market value [2] - Over the past five days, the main capital inflow was 261 million yuan, representing 5.01% of its circulating market value [2]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-044 成都市贝瑞和康基因技术股份有限公司 关于全资子公司基因测序仪获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 成都市贝瑞和康基因技术股份有限公司（以下简称"公司"）全资子公司杭 州贝瑞和康基因诊断技术有限公司的NovaSeq™ 6000Dx-CN-BG基因测序仪于近日 正式获得国家药品监督管理局（NMPA）颁发的医疗器械注册证（注册证编号：国 械注准20253221734）。现将具体情况公告如下： | 产品名称 | 基因测序仪 | | --- | --- | | 注册人名称 | 杭州贝瑞和康基因诊断技术有限公司 | | 注册证编号 | 国械注准20253221734 | | 型号及规格 | NovaSeqTM 6000Dx-CN-BG | | 有效期 | 2025年8月25日至2030年8月24日 | | 结构及组成 | 产品功能上由移液模块，光学模块，数据处理模块和触屏显示控制部分组成。 结构上由一个触摸显示器，一个状态显示区，一个测序芯片室和一个试剂存 | | ...

Core Viewpoint - Berry Genomics (000710) announced that its wholly-owned subsidiary, Hangzhou Berry Genomics and Health Technology Co., Ltd., has recently received a medical device registration certificate from the National Medical Products Administration for its NovaSeq6000Dx-CN-BG gene sequencer, which can meet various genetic testing needs for the three-level prevention of birth defects [1] Company Summary - The NovaSeq6000Dx-CN-BG high-throughput sequencer is designed to fulfill the genetic testing requirements related to the prevention of birth defects [1]

Core Viewpoint - Berry Genomics' subsidiary has received a medical device registration certificate for its NovaSeq™6000Dx-CN-BG gene sequencer, indicating a significant advancement in the company's product offerings in the field of DNA sequencing [1]. Company Summary - Berry Genomics announced that its wholly-owned subsidiary, Hangzhou Berry Genomics Technology Co., Ltd., has obtained a medical device registration certificate from the National Medical Products Administration for the NovaSeq™6000Dx-CN-BG gene sequencer [1]. - The NovaSeq™6000Dx-CN-BG utilizes reversible terminator sequencing technology, which is clinically applied for human deoxyribonucleic acid (DNA) sequencing [1].